Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Por Tang, P.A., Hay, A.E., O’Callaghan, C.J., Mittmann, N., Chambers, C.R., Pater, J.L., Leighl, N.B.
Publicado no Curr Oncol (2016)